Characteristics of individual patients.
| No. | Age/ sex |
Stage at the time of diagnosis | Prior regimen used | Previous N of therapy | Diagnosis to VIBE (mo) | Stage before VIBE | VIBE cycles | Response after VIBE | Auto HSCT yes/no |
|---|---|---|---|---|---|---|---|---|---|
| Relapsed cases of cHL | |||||||||
| 1 | 21/F | II-A | ABVD×6 (2012)-CR, IFRT 30Gy, GDP×4 (2013)-PD | 3 | 22 | III | 2 | CR | Yes |
| 2 | 28/M | II-B | ABVD×6 (2014)-CR, GDP×3 (2016)-PR | 2 | 31 | III | 2 | CRU | Yes |
| 3 | 13/M | II-A | ABVD×6 (2013)-CR, GDP×4 (2016)-SD | 2 | 54 | III | 2 | CRU | Yes |
| 4 | 25/M | II-AX | ABVD×6 (2014)-CR, Bendamustine×2, RT (PR) GDP×2-PR, Nivolumab×8 doses-PR but soon progressed |
2 | 41 | III | 2 | PD | No |
| 5 | 15/M | II-B | ABVD×6 (2010)-CR, IEV×4 RT to mediastinum (2012)-CR, GDP×2 (2019)-SD | 4 | 90 | III | 3 |
CR | Yes |
| 6 | 13/M | III-B | ABVD×6 (2016)-CR GDP×2 (2019)-PD |
2 | 44 | III | 3 | CRU | No |
| 7 | 29/M | III-BS | ABVD×6 (2016)-CR | 1 | 48 | III | 4 | CRU | Yes |
| Primary refractory cases of cHL | |||||||||
| 8 | 21/M | III-BEX | ABVD×4 (2013)-PR, BEACOPP×3 (2013)-PR, IFRT 30 Gy, GDP× (2014)-PR | 4 | 20 | I | 2 | CR | Yes |
| 9 | 20/M | III-B | COPP×1 BEACOPP×5,-PD |
2 | 6 | III | 2 | PD | No |
| 10 | 60/M | IV -BS | ABVD×6 (2016)-PD, Splenectomy | 2 | 16 | IV | 4 | CR | No |
| 11 | 27/M | IV-AE | CHV+Bleomycin, Etoposide×6 (2014)-PR DHAP×2 (2014)-PD, ICE×4 (2015)-SD |
3 | 27 | IV | 4 | CR | Yes |
| 12 | 26/M | IV-BE | ABVD×6 (2016)-PD | 1 | 8 | IV | 3 | CRU | Yes |
| 13 | 33/M | IV AEX | ABVD×4 (2015)-SD, GDP×4 (2016)-PD |
2 | 20 | IV | 4 | CRU | Yes |
| 14 | 27/M | II-A | ABVD×4 (2017)-PD | 1 | 5 | III | 4 | CR | Yes |
| 15 | 18/M | III BX | ABVD×4 (2015)-SD | 1 | 5 | III | 3 | CR | No |
| 16 | 27/F | II-BX | ABVD×6 (2017) PR, GDP×2 (2018)-PR, IFRT-PD | 3 | 13 | I | 4 | PR | No |
| 17 | 21/F | IV-B | ABVD×6 (2018) PR, GDP×2 (2019)-PR | 2 | 12 | IV | 3 | CRU | No |
| 18 | 21/M | III-B | ABVD×6 (2018) PD, GDP×4 (2019)-PD | 2 | 10 | III | 3 | CR | Yes |
| 19 | 26/M | IVB | ABVD×5 (2018)-SD GDP×2 (2019)-PR |
2 | 24 | IV | 4 | PD | No |
| 20 | 25/M | IVBE | COPP×1 ABVD×5 (2019)-PD GDP×2 (2019)-PD |
2 | 15 | IV | 2 | SD | No |
| 21 | 14/F | IVA | COPP×2 (2019)-PR ABVD×6 (2020)-PD |
2 | 13 | II | 3 | CR | Yes |
| 22 | 28/F | IVBS | ABVD×6 (2019)-PR | 1 | 25 | IV | 4 | PD | No |
| 23 | 22/f | II-B | ABVD×6 (2018)-PD, GDP×2 (2019)-SD | 2 | 19 | IV | 2 | CRU | No |
| 24 | 25/m | III-A | ABVD×6 (2012-13)-PD COPP×6 (2013)-PD IFRT 10 Fr (2015), CEP×3 (2016)-PR |
4 | 60 | III | 2 | CR | No |
Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, cytarabine, cyclophosphamide, oncovin, procarbazine, prednisolone; COPP, cyclophosphamide, oncovin, procarbazine, prednisolone; CR, complete remission; CRU, complete remission unconfirmed; DHAP, dexamethasone, cytarabine, cisplatin; GDP, Gemcitabine, dexamethasone, cisplatin; ICE, ifosfamide, carboplatin, etoposide; IFRT, involved field radiotherapy; PD, progressive disease; PR, partial remission; SD, stable disease.
Blood Res 2021;56:134~140 https://doi.org/10.5045/br.2021.2021039
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd